- ►washington.edu [PDF] UI Schwarz, MD Ritchie, Y Bradford, C Li, … - New England Journal of Medicine, 2008 - content.nejm.org Results As compared with patients with the non-A/non-A haplotype, patients with
the A/A haplotype of VKORC1 had a decreased time to the first INR within the
therapeutic range (P=0.02) and to the first INR of more than 4 (P=0.003). ... Cited by 132 - Related articles - BL Direct - All 28 versions
Y Caraco, S Blotnick, M Muszkat - Clinical Pharmacology & Therapeutics, 2007 - nature.com Warfarin anticoagulation effect is characterized by marked variability, some of
which has been attributed to CYP2C9 polymorphisms. This study prospectively
examines whether a priori knowledge of CYP2C9 genotype may improve warfarin ... Cited by 83 - Related articles - All 4 versions
H Schelleman, Z Chen, C Kealey, AS … - Age (years) - cceb.upenn.edu The objective of this study was to determine whether two vitamin K epoxide
reductase complex 1 (VKORC1) polymorphisms contribute to the variability in
warfarin response, particularly in African Americans. The effect of the ... Cited by 38 - Related articles - View as HTML - All 5 versions
T Schalekamp, BP Brasse, JFM Roijers, E … - Clinical pharmacology and therapeutics, 2007 - medicine.iupui.edu In a prospective follow-up study of the effects of VKORC1 and CYP2C9 genotypes
on the anticoagulation status of patients, we assessed the CYP2C9 and the VKORC1
C1173T genotypes of patients during the initial 6 months of phenprocoumon ... Cited by 33 - Related articles - View as HTML - All 9 versions
MR McClain, GE Palomaki, M Piper, JE … - Genetics in Medicine, 2008 - journals.lww.com Purpose: Summarize evidence regarding genetic testing in adults to inform
warfarin dosing to reduce adverse drug events such as serious bleeding. Methods:
Review published (and selected gray) literature using the Rapid-ACCE ... Cited by 21 - Related articles - BL Direct - All 3 versions
DC Crawford, MD Ritchie, MJ Rieder - Pharmacogenomics, 2007 - Future Medicine Genotype–phenotype studies in pharmacogenomics promise to identify the genetic
factors that contribute substantially to variation in individual drug response.
While most genetic association studies have failed to deliver this promise, ... Cited by 15 - Related articles - BL Direct - All 4 versions
MIM Abdul, X Jiang, KM Williams, RO Day, … - British Journal of Pharmacology, 2008 - pubmedcentral.nih.gov Patients commonly take complementary medicines in conjunction with warfarin yet
evidence supporting the safety or the risk of a herb–drug interaction is
lacking. The aim of this study was to investigate the possible impact of ... Cited by 14 - Related articles - All 5 versions
H Schelleman, J Chen, Z Chen, J Christie, … - Clinical pharmacology and therapeutics, 2008 - pubmedcentral.nih.gov The objective of this study was to determine whether clinical, environmental,
and genetic factors can be used to develop dosing algorithms for Caucasians and
African Americans that perform better than giving empirical 5 mg/day. Cited by 12 - Related articles - All 5 versions
LM Meckley, AK Wittkowsky, MJ Rieder, AE … - Thrombosis and haemostasis, 2008 - ncbi.nlm.nih.gov The objective of this study was to assess the relative influence of VKORC1 and
CYP2C9 genetic variants on several clinical outcomes related to warfarin
treatment. We conducted a retrospective cohort analysis of 172 ... Cited by 13 - Related articles - All 3 versions
- ►hematologylibrary.org C Li, UI Schwarz, MD Ritchie, DM Roden, CM … - Blood, 2009 - bloodjournal.hematologylibrary.org Genetic variants in CYP2C9 and VKORC1 strongly affect steady-state warfarin
dose. However, these variants also affect early international normalized ratio
(INR) values during warfarin initiation. We examined whether CYP2C9/VKORC1 ... Cited by 6 - Related articles - All 4 versions
